Mehta Named Deputy Director at Miami Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MINESH MEHTA joined Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology.

Mehta comes to Baptist Health from the University of Maryland School of Medicine, where he served as medical director of the Maryland Proton Treatment Center in Baltimore—the area’s first proton treatment center, which he helped to launch.

Mehta was also the university’s associate director of clinical research in the Department of Radiation Oncology. Prior to his time at Maryland, he held academic, research and administrative leadership positions at Northwestern University and the University of Wisconsin, where he was appointed chairman of the medical school’s Department of Human Oncology and led research studies, technology development and expansion at the University of Wisconsin Cancer Center. He also headed the university’s brain tumor program for more than 15 years. At the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Mehta was co-director of the Radiation Oncology Residency Training Program.

The Miami Cancer Institute’s new $430-million proton therapy facility, opening in 2016 and located on the Baptist Hospital of Miami campus, expects to treat its first patient with proton therapy in 2017.

YOU MAY BE INTERESTED IN

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login